Could PAA’s lead cancer drug treatment treat COVID-19?
Published 17-APR-2020 10:26 A.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
PharmAust Limited (ASX: PAA) has entered into a Materials Transfer Agreement with the Walter and Eliza Hall Institute of Medical Research (WEHI) to test the effects of monepantel (MPL) on COVID-19 infections.
Monepantel is PharmAust’s lead drug candidate. It is a novel, potent and safe inhibitor of the mTOR pathway – a key driver of cancer.
MPL has been evaluated in Phase 1 clinical trials in humans and dogs; was well tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug in Phase 2 clinical trials.
Given the advancing nature of Monapantel, there is further community value in testing whether Monepantel’s mechanism of action in cancer may also prove to be beneficial in the treatment of certain viral diseases such as COVID-19.
There are currently no specific vaccines or treatments for COVID-19, however there are several clinical trials being conducted around the world to evaluate potential treatments.
Under the Transfer Agreement studies will be conducted by WEHI researcher and joint head of the Institute’s Infectious Diseases and Immune Defence division Professor Marc Pellegrini (MBBS BSc FRACP PhD FAHMS).
Professor Pellegrini is also an infectious disease clinician at the Royal Melbourne Hospital and is the recipient of an Australian National Health and Medical Research Council Excellence Award for his work on chronic infections.
Importantly for PharmAust, it will own all intellectual property results and rights generated from the studies.
PharmAust will pay a nominal fee to WEHI for undertaking the studies using monepantel and monepantel sulfone.
“We are delighted to be working with the Walter and Eliza Hall Institute of Medical Research on this timely and important project and delighted that Professor Marc Pellegrini has agreed to be the Investigator, ” PharmAust’s Executive Chairman Dr Roger Aston said.
The studies will commence shortly with preliminary data estimated to be delivered by WEIHI in May 2020.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
